RNS Number : 6311N
Shield Therapeutics PLC
30 September 2021

Shield Therapeutics plc
("Shield" or the "Group")

Block Listing 6 Monthly Return

Date: 30 September 2021

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention Share Plan		
Period of return:	From:	01 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:		39,794		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		39,794		

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan		
Period of return:	From:	01 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:		388,079		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		-47,059		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		341,020		

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan		
Period of return:	From:	01 April 2021	To:	30 September 2021

Balance of unallotted securities under scheme(s) from previous return:	24,273
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):	NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	24,273

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan		
Period of return:	From:	01 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:		3,178,276		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		3,178,276		

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	+44 (0) 191 511 8500

For further information, please contact:

Shield Therapeutics plc +44 (0) 191 511 8500
Greg Madison (CEO)
Hans-Peter Rudolf (CFO)

Peel Hunt LLP - **Nominated Adviser & Joint Broker** +44 (0) 20 7148 8900

James Steel / Christopher Golden

finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne/ Alice Woodings or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREAKNEDAEFEFA